Tyra Biosciences Management
Management criteria checks 2/4
Tyra Biosciences' CEO is Todd Harris, appointed in Aug 2018, has a tenure of 7.58 years. total yearly compensation is $7.57M, comprised of 8.4% salary and 91.6% bonuses, including company stock and options. directly owns 2.52% of the company’s shares, worth $50.47M. The average tenure of the management team and the board of directors is 3.8 years and 5.6 years respectively.
Key information
Todd Harris
Chief executive officer
US$7.6m
Total compensation
| CEO salary percentage | 8.36% |
| CEO tenure | 7.6yrs |
| CEO ownership | 2.5% |
| Management average tenure | 3.8yrs |
| Board average tenure | 5.6yrs |
Recent management updates
Recent updates
We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth
Oct 01
Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
Mar 28Tyra Biosciences: FGFR1/2 Driven AE Data Spooked The Market
Mar 01The Take On Tyra Biosciences
Dec 17We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate
Dec 11Calculating The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)
Oct 21Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point
Oct 21Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation
Aug 29Lots Of Bullish Signals, But No Revenue Or Earnings From Tyra Biosciences
Jul 23A Look At The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)
Jul 05We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate
May 13We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate
Jan 13We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth
Sep 27Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
Jun 13Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
Feb 23Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
Nov 09Tyra Biosciences GAAP EPS of -$0.36
Aug 04Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation
Jul 21Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation
Mar 31Companies Like Tyra Biosciences (NASDAQ:TYRA) Are In A Position To Invest In Growth
Dec 15CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | -US$120m |
| Sep 30 2025 | n/a | n/a | -US$112m |
| Jun 30 2025 | n/a | n/a | -US$106m |
| Mar 31 2025 | n/a | n/a | -US$96m |
| Dec 31 2024 | US$8m | US$633k | -US$86m |
| Sep 30 2024 | n/a | n/a | -US$84m |
| Jun 30 2024 | n/a | n/a | -US$81m |
| Mar 31 2024 | n/a | n/a | -US$75m |
| Dec 31 2023 | US$5m | US$608k | -US$69m |
| Sep 30 2023 | n/a | n/a | -US$59m |
| Jun 30 2023 | n/a | n/a | -US$51m |
| Mar 31 2023 | n/a | n/a | -US$52m |
| Dec 31 2022 | US$2m | US$581k | -US$55m |
| Sep 30 2022 | n/a | n/a | -US$52m |
| Jun 30 2022 | n/a | n/a | -US$46m |
| Mar 31 2022 | n/a | n/a | -US$37m |
| Dec 31 2021 | US$6m | US$443k | -US$26m |
| Sep 30 2021 | n/a | n/a | -US$20m |
| Jun 30 2021 | n/a | n/a | -US$16m |
| Mar 31 2021 | n/a | n/a | -US$12m |
| Dec 31 2020 | US$1m | US$350k | -US$9m |
Compensation vs Market: Todd's total compensation ($USD7.57M) is above average for companies of similar size in the US market ($USD5.35M).
Compensation vs Earnings: Todd's compensation has increased whilst the company is unprofitable.
CEO
Todd Harris (46 yo)
Dr. Todd Harris, Ph D., co-founded Tyra Biosciences, Inc. and serves as President and Chief Executive Officer since November 2018 and Director since August 2018 and had been its Secretary November 2018 and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 7.6yrs | US$7.57m | 2.52% $ 50.5m | |
| Co-Founder & Chief Discovery Officer | 7.6yrs | US$2.66m | 0.27% $ 5.5m | |
| Chief Medical Officer | 1.5yrs | US$5.10m | no data | |
| Chief Financial Officer | 3.2yrs | US$3.53m | 0.030% $ 600.5k | |
| Chief Operating Officer | less than a year | no data | no data | |
| Chief Technology Officer | 5.2yrs | no data | no data | |
| Chief Scientific Officer | 6.2yrs | US$2.53m | no data | |
| General Counsel & Secretary | 3.8yrs | US$2.76m | no data | |
| Senior VP of Corporate Development & Strategy | 3.7yrs | no data | no data | |
| Chief Human Resources Officer | 1.8yrs | no data | no data | |
| Chief Development Officer | 5.2yrs | no data | no data | |
| Senior Vice President of Clinical Development | no data | no data | no data |
Experienced Management: TYRA's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 7.6yrs | US$7.57m | 2.52% $ 50.5m | |
| Independent Director | 7.3yrs | US$305.69k | 0% $ 0 | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 7yrs | US$269.19k | 0.052% $ 1.0m | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 4.8yrs | US$275.19k | 0% $ 0 | |
| Independent Director | 1.8yrs | US$543.55k | 0% $ 0 | |
| Independent Director | 5yrs | no data | no data | |
| Independent Director | 6.2yrs | US$274.19k | 0% $ 0 | |
| Independent Director | 1.8yrs | US$546.81k | 0% $ 0 | |
| Scientific Advisor | no data | no data | no data |
Experienced Board: TYRA's board of directors are considered experienced (5.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/23 07:29 |
| End of Day Share Price | 2026/03/23 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tyra Biosciences, Inc. is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eliana Merle | Barclays |
| Jason Zemansky | BofA Global Research |
| Li Wang Watsek | Cantor Fitzgerald & Co. |